Par Pharmaceutical Hit With Securities Suits
Drugmaker Par Pharmaceutical Companies, Inc. has been hit with a lawsuit alleging the company misled investors and overstated its revenue by at least $55 million....To view the full article, register now.
Already a subscriber? Click here to view full article